Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Supporting the call for a gender-neutral human papillomavirus vaccination in Canada

Cyra Patel and Kristine Macartney
CMAJ January 23, 2017 189 (3) E118; DOI: https://doi.org/10.1503/cmaj.732446
Cyra Patel
Research Officer, National Centre for Immunisation Research and Surveillance, Westmead NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristine Macartney
Deputy Director, National Centre for Immunisation Research and Surveillance, Westmead NSW, Australia, and Associate Professor, University of Sydney, School of Child and Adolescent Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

We commend Shapiro and colleagues1 on their recent policy analysis of human papillomavirus (HPV) vaccination for males in Canada and their call for gender-neutral programs in all provinces and territories.

Australia has the highest uptake of HPV vaccine in males at a country-level worldwide; we write to add evidence that may inform Canada’s approach. Quadrivalent HPV vaccine was included for males under the Australian National Immunisation Program from February 2013, following introduction for females in 2007. Australia’s nationally centralized systems for economic assessment and vaccine procurement facilitate program decisions: inclusion was deemed cost-effective, albeit at an undisclosed price.2

The gender-neutral HPV vaccination program received support even before the female vaccination program commenced.3 Uptake in males was high in the first year of the additional program and has increased: 77.0%, 74.0% and 66.4% of boys turning 15 years of age had received one, two and three doses, respectively, by 2015.4 HPV vaccination coverage for females has also increased by about 6% since male immunization was funded (from 71.0% to 77.4% for three-dose coverage between 2013 and 2015).4 Targeting all young people allows more consistent framing of HPV vaccination as a cancer prevention strategy and has likely somewhat negated the vaccine resistance observed in Australia and in other countries. A strong communications strategy, together with strengthening vaccine safety surveillance,5 has also facilitated vaccine uptake.

Increasing recognition and incidence of HPV-related diseases like anal and oropharyngeal cancers6 and growing evidence of vaccine immunogenicity, safety and efficacy in males from clinical trials7 underpins establishment of equitable HPV vaccination programs. Reliance on herd immunity from a female HPV vaccination program to protect males against HPV-associated disease is arguably unethical, particularly in the context of demonstrated cost-effectiveness in high-income countries. We fully support our colleagues in their efforts to advocate for equitable HPV vaccination throughout Canada.

References

  1. ↵
    1. Shapiro GK,
    2. Perez S,
    3. Rosberger Z
    . Rosberger. Including males in Canadian human papillomavirus vaccination programs: a policy analysis. CMAJ 2016; 188:881–6.
    OpenUrlFREE Full Text
  2. ↵
    1. Georgousakis M,
    2. Jayasinghe S,
    3. Brotherton J,
    4. et al
    . Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis 2012;12:627–34.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Marshall H,
    2. Ryan P,
    3. Roberton D,
    4. et al
    . A cross-sectional survey to assess community attitudes to introduction of human papillomavirus vaccine. Aust N Z J Public Health 2007;31:235–42.
    OpenUrlCrossRefPubMed
  4. ↵
    National HPV Vaccination Program Register. Coverage data. Canberra (AU): Australian Government, Department of Health; 2016. Available: www.hpvregister.org.au/research/coverage-data (accessed 2016 June 27).
  5. ↵
    Enhanced school-based surveillance of acute adverse events following immunisation with human papillomavirus vaccine in males and females, 2013. Canberra (AU): Australian Government, Department of Health, Therapeutic Goods Administration; 2015.
  6. ↵
    1. Chaturvedi AK,
    2. Anderson WF,
    3. Lortet-Tieulent J,
    4. et al
    . Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013;31: 4550–9.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Goldstone SE,
    2. Jessen H,
    3. Palefsky JM,
    4. et al
    . Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine 2013;31:3849–55.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (3)
CMAJ
Vol. 189, Issue 3
23 Jan 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Supporting the call for a gender-neutral human papillomavirus vaccination in Canada
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Supporting the call for a gender-neutral human papillomavirus vaccination in Canada
Cyra Patel, Kristine Macartney
CMAJ Jan 2017, 189 (3) E118; DOI: 10.1503/cmaj.732446

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Supporting the call for a gender-neutral human papillomavirus vaccination in Canada
Cyra Patel, Kristine Macartney
CMAJ Jan 2017, 189 (3) E118; DOI: 10.1503/cmaj.732446
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Including males in Canadian human papillomavirus vaccination programs: a policy analysis
  • The authors respond to “Supporting the call for a gender-neutral human papillomavirus vaccination in Canada”
  • PubMed
  • Google Scholar

Cited By...

  • Investigating Canadian parents' HPV vaccine knowledge, attitudes and behaviour: a study protocol for a longitudinal national online survey
  • The authors respond to "Supporting the call for a gender-neutral human papillomavirus vaccination in Canada"
  • Google Scholar

More in this TOC Section

  • Responding to Bill C-7
  • Benefits of nirmatrelvir–ritonavir remain unproven for some populations
  • Renalism
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire